KEYNOTE-146: Lenvatinib Plus Pembrolizumab as Early-Line Treatment of Advanced Endometrial Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Lenvatinib plus pembrolizumab showed promising efficacy as early-line treatment for patients with advanced endometrial cancer that is not MSI-H or dMMR in this post hoc analysis of KEYNOTE-146.
Format: Microsoft PowerPoint (.ppt)
File Size: 208 KB
Released: June 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

In this slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

person default Mansoor Raza Mirza, MD Bradley J. Monk, MD, FACS, FACOG Prof Isabelle Ray Coquard Released: March 2, 2021

Domenica Lorusso, MD, PhD, on the molecular reclassification of endometrial cancers and key ongoing immunotherapy trials, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: February 25, 2021

From Clinical Care Options (CCO), Webcast and downloadable slides reviewing the latest data on the use of PARP inhibitors to treat newly diagnosed advanced ovarian cancer

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci
Program Director
person default Alexandra Leary, MD, PhD person default Frederik Marmé, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: February 19, 2021 Expired: February 18, 2022

In this slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

Domenica Lorusso, MD, PhD person default Mansoor Raza Mirza, MD Ana Oaknin, MD, PhD Released: January 5, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue